Basilea Pharmaceutica AG (BPMUF)
USD 47.5
(0.0%)
USD 47.5
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 173.28 Million CHF | -21.53% |
| 2022 | 220.84 Million CHF | -10.68% |
| 2021 | 247.26 Million CHF | 7.6% |
| 2020 | 229.79 Million CHF | 3.76% |
| 2019 | 221.46 Million CHF | -21.4% |
| 2018 | 281.75 Million CHF | -19.77% |
| 2017 | 351.16 Million CHF | 7.06% |
| 2016 | 328 Million CHF | -17.79% |
| 2015 | 399 Million CHF | 55.02% |
| 2014 | 257.37 Million CHF | -14.14% |
| 2013 | 299.75 Million CHF | -20.14% |
| 2012 | 375.34 Million CHF | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 188.66 Million CHF | 0.0% |
| 2023 Q1 | 230.03 Million CHF | 4.16% |
| 2023 Q2 | 230.03 Million CHF | 0.0% |
| 2023 Q3 | 173.28 Million CHF | -24.67% |
| 2023 Q4 | 173.28 Million CHF | 0.0% |
| 2023 FY | 173.28 Million CHF | -21.53% |
| 2022 Q1 | 236.07 Million CHF | -4.53% |
| 2022 Q3 | 220.84 Million CHF | -6.45% |
| 2022 Q4 | 220.84 Million CHF | 0.0% |
| 2022 FY | 220.84 Million CHF | -10.68% |
| 2022 Q2 | 236.07 Million CHF | 0.0% |
| 2021 Q3 | 247.26 Million CHF | 8.84% |
| 2021 Q1 | 227.17 Million CHF | -1.14% |
| 2021 FY | 247.26 Million CHF | 7.6% |
| 2021 Q2 | 227.17 Million CHF | 0.0% |
| 2021 Q4 | 247.26 Million CHF | 0.0% |
| 2020 Q3 | 229.79 Million CHF | 16.61% |
| 2020 Q4 | 229.79 Million CHF | 0.0% |
| 2020 Q1 | 197.05 Million CHF | -11.02% |
| 2020 FY | 229.79 Million CHF | 3.76% |
| 2020 Q2 | 197.05 Million CHF | 0.0% |
| 2019 Q2 | 235.64 Million CHF | 0.0% |
| 2019 Q4 | 221.46 Million CHF | 0.0% |
| 2019 Q1 | 235.64 Million CHF | -16.36% |
| 2019 Q3 | 221.46 Million CHF | -6.02% |
| 2019 FY | 221.46 Million CHF | -21.4% |
| 2018 FY | 281.75 Million CHF | -19.77% |
| 2018 Q4 | 281.75 Million CHF | 0.0% |
| 2018 Q3 | 281.75 Million CHF | -7.66% |
| 2018 Q2 | 305.1 Million CHF | 0.0% |
| 2018 Q1 | 305.1 Million CHF | -13.12% |
| 2017 Q2 | 293.89 Million CHF | 0.0% |
| 2017 FY | 351.16 Million CHF | 7.06% |
| 2017 Q4 | 351.16 Million CHF | 0.0% |
| 2017 Q3 | 351.16 Million CHF | 19.49% |
| 2017 Q1 | 293.89 Million CHF | -10.33% |
| 2016 Q3 | 327.75 Million CHF | -5.18% |
| 2016 FY | 328 Million CHF | -17.79% |
| 2016 Q2 | 345.65 Million CHF | 0.0% |
| 2016 Q1 | 345.65 Million CHF | -13.31% |
| 2016 Q4 | 327.75 Million CHF | 0.0% |
| 2015 FY | 399 Million CHF | 55.02% |
| 2015 Q4 | 398.73 Million CHF | 0.0% |
| 2015 Q3 | 398.73 Million CHF | 60.21% |
| 2015 Q1 | 248.87 Million CHF | -3.3% |
| 2015 Q2 | 248.87 Million CHF | 0.0% |
| 2014 Q1 | 274.33 Million CHF | -8.48% |
| 2014 Q3 | 257.37 Million CHF | -6.18% |
| 2014 Q2 | 274.33 Million CHF | 0.0% |
| 2014 FY | 257.37 Million CHF | -14.14% |
| 2014 Q4 | 257.37 Million CHF | 0.0% |
| 2013 FY | 299.75 Million CHF | -20.14% |
| 2013 Q1 | 290.27 Million CHF | -22.67% |
| 2013 Q2 | 290.27 Million CHF | 0.0% |
| 2013 Q3 | 299.75 Million CHF | 3.27% |
| 2013 Q4 | 299.75 Million CHF | 0.0% |
| 2012 Q4 | 375.34 Million CHF | 0.0% |
| 2012 Q3 | 375.34 Million CHF | 0.0% |
| 2012 FY | 375.34 Million CHF | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 10.55 Million USD | -1541.927% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -8749.452% |
| CSL Limited | 38.02 Billion USD | 99.544% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -33.083% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -48904.714% |
| BioStem Technologies, Inc. | 14.56 Million USD | -1090.148% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -228.815% |
| Qrons Inc. | 420.00 USD | -41259185.714% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -31286.112% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -520.13% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -477.342% |
| Skye Bioscience, Inc. | 11.94 Million USD | -1351.282% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -35960.03% |
| Rebus Holdings, Inc. | 5000.00 USD | -3465680.0% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -25106.186% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -7501588.312% |
| Genscript Biotech Corporation | 3.38 Billion USD | 94.883% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -22386.258% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -346.081% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -2300.204% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -226854.711% |
| SQZ Biotechnologies Company | 107.18 Million USD | -61.67% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -12000.917% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -239365.211% |
| Mesoblast Limited | 667.9 Million USD | 74.055% |
| Marizyme, Inc. | 22.01 Million USD | -687.138% |
| Genus plc | 1.02 Billion USD | 83.158% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -12657.288% |
| Pharming Group N.V. | 462.85 Million USD | 62.561% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -5130.558% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -34624.541% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -27537.799% |
| ContraFect Corporation | 20.67 Million USD | -737.995% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -44291.417% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -45242.603% |
| IMV Inc. | 31.33 Million USD | -453.042% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -4079.645% |
| MultiCell Technologies, Inc. | 126.22 USD | -137291137.522% |
| ONE Bio Corp. | 70.08 Million USD | -147.254% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -18341.101% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -34.845% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -40039.768% |
| Q BioMed Inc. | 3.51 Million USD | -4829.261% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -392.592% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -66223.863% |
| Biomind Labs Inc. | 73.81 Thousand USD | -234648.506% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 61.173% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -11860.509% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -6209.827% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -6556.779% |
| GB Sciences, Inc. | 103.44 Thousand USD | -167422.863% |
| Alpha Cognition Inc. | 2.45 Million USD | -6966.761% |
| HST Global, Inc. | 1526.00 USD | -11355666.71% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -17439.958% |
| Halberd Corporation | 10.13 Thousand USD | -1710382.677% |
| Enzolytics Inc. | 361.7 Million USD | 52.091% |
| Agentix Corp. | 261.39 Thousand USD | -66194.684% |
| Resverlogix Corp. | 8.11 Million USD | -2035.416% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -9127.906% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 96.185% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -263.274% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -26990.968% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -760573.368% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -1836.373% |
| AVAX Technologies, Inc. | 7.37 Million USD | -2248.994% |
| Zenith Capital Corp. | 7410.00 USD | -2338482.996% |
| Ember Therapeutics, Inc. | 184.00 USD | -94178704.348% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -53748.903% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -66201.786% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -18574.168% |
| Kadimastem Ltd | 2.3 Million USD | -7420.963% |
| Helix BioMedix, Inc. | 3.02 Million USD | -5628.399% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -303415.256% |
| LadRx Corporation | 2.3 Million USD | -7408.573% |
| Cell Source, Inc. | 195.17 Thousand USD | -88688.293% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -48904.714% |
| NovAccess Global Inc. | 62.24 Thousand USD | -278284.848% |
| Affymax, Inc. | 7.44 Million USD | -2228.214% |
| Itoco Inc. | 1.4 Million USD | -12277.149% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -181056.633% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -163380.189% |
| Mobile Lads Corp. | 52.00 USD | -333247976.923% |
| CytoDyn Inc. | 11.13 Million USD | -1456.115% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -121104.851% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -969077.852% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -44855.133% |
| SYBLEU INC | 330.46 Thousand USD | -52337.452% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -42225.278% |
| International Stem Cell Corporation | 5.39 Million USD | -3115.009% |
| Bioxytran, Inc. | 137.63 Thousand USD | -125802.004% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -1055.119% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -945.232% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -219253.165% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -19940.894% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -2205.295% |
| Neutra Corp. | 2851.00 USD | -6078083.094% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -434.744% |
| PureTech Health plc | 693.97 Million USD | 75.029% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -2047.034% |
| IXICO plc | 15.84 Million USD | -993.727% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -1992.357% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -67.714% |
| CSL Limited | 38.02 Billion USD | 99.544% |
| Cellectis S.A. | 333.99 Million USD | 48.116% |